Affinage

RUNX2

Runt-related transcription factor 2 · UniProt Q13950

Length
521 aa
Mass
56.6 kDa
Annotated
2026-06-10
100 papers in source corpus 37 papers cited in narrative 38 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RUNX2 is the master transcription factor governing osteoblast differentiation, chondrocyte maturation, and skeletal morphogenesis, originally identified as the factor binding the osteoblast-specific OSE2 element in the osteocalcin promoter whose forced expression in non-osteoblastic cells activates the osteoblast gene program (PMID:9182762, PMID:9215522). As a sequence-specific activator, RUNX2 binds Runx-consensus elements to directly regulate a broad target repertoire including galectin-3 (PMID:12604608), SOST (PMID:14739291, PMID:27154028), survivin (PMID:19949374), DICER (PMID:27064596), bone sialoprotein (PMID:12750290), and cell-cycle genes controlling chondrocyte proliferation (PMID:24862038), and it autoregulates its own promoter through negative feedback (PMID:10911365). Beyond classical promoter activation, RUNX2 acts as a pioneer-like factor that establishes chromatin accessibility at osteoblast-specific enhancers, including a Runx2-dependent Sp7 enhancer (PMID:36070691). Its skeletal functions are essential and stage-specific: it drives transdifferentiation of hypertrophic chondrocytes into osteoblasts (PMID:33253203), cooperates with Runx1 to control sternal morphogenesis via Sox5/Sox6 (PMID:20181744), and its own osteoblast-specific expression is set by a distal enhancer bound by Dlx5 and Mef2c (PMID:24692107). RUNX2 transcriptional output is shaped by physical partners including the heterodimerization factor CBFβ, which is required for efficient DNA binding and protein stability (PMID:12811622), Sp7/Osterix (PMID:25158187, PMID:27154028), and Smad3, which represses RUNX2 to mediate TGF-β inhibition of osteoblast differentiation (PMID:11331591). RUNX2 stability and activity are extensively tuned by post-translational modification: p300-mediated acetylation enhances activity and blocks Smurf1-dependent degradation, while HDAC4/5 reverse this (PMID:16613856); CK2 phosphorylation recruits the deubiquitinase HAUSP to stabilize RUNX2 and drive osteoprogenitor commitment (PMID:32385263); and E3 ligases CHIP/STUB1 and Smurf1/2 (the latter via the Smad6 adaptor and antagonized by Akt) target RUNX2 for proteasomal degradation (PMID:18541707, PMID:16299379, PMID:24961731). Redox state further controls RUNX2 abundance, as glutathione protects it from ROS-induced degradation (PMID:37432749) and 4-HNE carbonylation at Lys176 stabilizes it to promote vascular smooth muscle calcification (PMID:38348663). Subnuclear targeting via the C-terminal nuclear matrix-targeting signal and CRM1/microtubule-dependent shuttling are required for its function in osteolytic, invasive, and metastatic contexts (PMID:15665096, PMID:16110492, PMID:12750290), and RUNX2 also drives pathological fibroblast programs in pulmonary fibrosis (PMID:39910313).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1997 High

    Established RUNX2 as the osteoblast-specific transcription factor that binds the OSE2 element and is sufficient to switch on the osteoblast gene program, defining its identity as a master differentiation regulator.

    Evidence cDNA cloning, DNA-binding assays, and forced expression in non-osteoblastic cells; antibody supershift and antisense knockdown in primary osteoblasts

    PMID:9182762 PMID:9215522

    Open questions at the time
    • Did not define upstream signals controlling RUNX2 expression
    • Did not resolve cofactor requirements for target selectivity
  2. 2000 High

    Showed RUNX2 binds and represses its own promoter, revealing a negative autoregulatory feedback loop that constrains its own levels.

    Evidence Deletion analysis, EMSA, and promoter-reporter assays with forced expression

    PMID:10911365

    Open questions at the time
    • Functional consequence of autosuppression in vivo not established
    • Cofactors at the autoregulatory site not defined
  3. 2001 High

    Identified Smad3 as a direct RUNX2-interacting repressor, explaining how TGF-β signaling inhibits osteoblast differentiation through dual repression of RUNX2 activity and gene transcription.

    Evidence Co-IP, cell-type-specific reporter assays, gain/loss-of-function

    PMID:11331591

    Open questions at the time
    • Interaction interface on RUNX2 not finely mapped
    • Mechanism of cell-type specificity (mesenchymal vs epithelial) unresolved
  4. 2003 Medium

    Defined RUNX2 partnership with the obligate heterodimer subunit CBFβ and the osteoblast factor Sp7/Osterix, establishing the core complexes required for efficient DNA binding, stability, and synergistic target activation.

    Evidence Heterodimer/DNA-binding and ubiquitination assays for CBFβ; endogenous Co-IP and synergistic reporter assays for Sp7

    PMID:12811622 PMID:25158187

    Open questions at the time
    • Structural basis of Sp7-RUNX2 synergy not resolved
    • CBFβ stabilization mechanism described largely in review context
  5. 2003 Medium

    Expanded the direct target repertoire and showed RUNX2 can be ectopically activated outside bone, linking it to galectin-3, survivin, bone sialoprotein and cancer cell behavior.

    Evidence EMSA/ChIP, forced expression, knockout mice, and reporter assays in mesenchymal and cancer cell lines

    PMID:12604608 PMID:12750290 PMID:19949374

    Open questions at the time
    • Some targets validated only by reporter assays in cell lines
    • Cofactor context for cancer-specific activation undefined
  6. 2006 High

    Revealed that RUNX2 activity and stability are governed by competing acetylation and deacetylation, integrating BMP-2 signaling with Smurf1-mediated degradation.

    Evidence In vivo acetylation, Co-IP, ubiquitination assays, HDAC inhibition, and differentiation assays; HDAC6 recruitment shown earlier

    PMID:12391164 PMID:16613856

    Open questions at the time
    • Acetylation site stoichiometry not quantified
    • Interplay with phosphorylation marks not integrated
  7. 2008 High

    Identified E3 ligases (CHIP/STUB1, Smurf1 via Smad6 adaptor) controlling RUNX2 turnover and the osteoblast-versus-adipocyte fate decision.

    Evidence Co-IP, in vitro binding, ubiquitination assays, siRNA and overexpression with differentiation readouts

    PMID:16299379 PMID:18541707

    Open questions at the time
    • Lysine residues ubiquitinated not mapped
    • Signals selecting among competing E3 ligases unclear
  8. 2006 High

    Established that RUNX2 subnuclear targeting via its NMTS and CRM1/microtubule-dependent shuttling are required for its functional output in osteolytic and metastatic settings.

    Evidence NMTS mutagenesis with in vivo osteolysis/invasion assays; CRM1 and taxol pharmacology plus tubulin Co-IP

    PMID:15665096 PMID:16110492

    Open questions at the time
    • Identity of nuclear matrix docking partners unknown
    • Physiological trigger for cytoplasmic shuttling undefined
  9. 2014 High

    Dissected the C-terminal (exon 8) domain requirement for chondrocyte function and identified the distal enhancer plus Dlx5/Mef2c machinery setting osteoblast-specific RUNX2 expression.

    Evidence Conditional exon-8 deletion with ChIP; BAC-GFP reporter mice, ChIP, mutagenesis, and histone-modification profiling

    PMID:24692107 PMID:24862038

    Open questions at the time
    • How C-terminal activity is molecularly transmitted to chromatin not resolved
    • Combinatorial enhancer logic across cell types incomplete
  10. 2020 High

    Defined a CK2/HAUSP phosphorylation-deubiquitination axis that stabilizes RUNX2 and is required for skeletal stem cell commitment and heterotopic ossification.

    Evidence In vitro kinase assay, Co-IP, ubiquitination assays, genetic deletion and pharmacological inhibition in ossification models

    PMID:32385263

    Open questions at the time
    • CK2 phosphosites on RUNX2 not enumerated here
    • Crosstalk with E3-ligase pathways not integrated
  11. 2022 High

    Demonstrated RUNX2 acts as a chromatin-accessibility-establishing factor at cell-type-distinct osteoblast enhancers, including a Runx2-dependent Sp7 enhancer, elevating it from promoter activator to pioneer-like regulator.

    Evidence ATAC-seq, ChIP-seq, conditional knockout, reprogramming, and enhancer reporter assays in neonatal cells

    PMID:36070691

    Open questions at the time
    • Mechanism of nucleosome engagement not defined
    • Chromatin remodeler partners not identified
  12. 2025 High

    Extended RUNX2 function beyond skeleton, showing it drives pathological fibroblast programs and matrix deposition in pulmonary fibrosis.

    Evidence Conditional deletion with two Cre lines, scRNA-seq, scATAC-seq across fibrosis models

    PMID:39910313

    Open questions at the time
    • Direct fibrotic target genes not enumerated
    • Upstream activator of RUNX2 in LEPR+ fibroblasts unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the many post-translational modifications, cofactors, and chromatin-pioneering activities are integrated into a single decision logic that selects RUNX2 targets in different lineages and disease contexts remains unresolved.
  • No unified model linking modification state to genome-wide target selection
  • Quantitative hierarchy among competing stabilizing/destabilizing pathways unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 10 GO:0003677 DNA binding 5
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 1
Pathway
R-HSA-392499 Metabolism of proteins 7 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 4
Partners
CBFBDDX5HDAC6SMAD3SMAD6SP7STUB1XBP1
Complex memberships
RUNX2-CBFβ heterodimer

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 Osf2/Cbfa1 (RUNX2) was identified as the transcription factor that binds the osteoblast-specific cis-acting element OSE2 in the Osteocalcin promoter, and forced expression of Osf2/Cbfa1 in nonosteoblastic cells induces expression of the principal osteoblast-specific genes, establishing it as an osteoblast-specific transcriptional activator of osteoblast differentiation. cDNA cloning, DNA binding assays, forced expression in nonosteoblastic cells, gene expression analysis Cell High 9182762
1997 AML3/CBFA1 (RUNX2) is the specific AML family member present in the osteoblast-specific promoter binding complex; antibody supershift assays confirmed AML-3 is the component of this complex in primary rat osteoblasts, and antisense knockdown of runt homology domain proteins reduced alkaline phosphatase-positive cells, osteocalcin production, and mineralized nodule formation. Electrophoretic mobility shift assay (EMSA) with antibody supershift, antisense oligonucleotide knockdown, differentiation assays Journal of cellular biochemistry High 9215522
2001 TGF-β inhibits osteoblast differentiation via Smad3, which physically interacts with CBFA1/RUNX2 and represses its transcriptional activity at the CBFA1-binding OSE2 promoter sequence in mesenchymal but not epithelial cells; Smad3 also inhibits cbfa1 gene transcription, providing a dual repression mechanism. Co-immunoprecipitation, reporter gene assays, cell-type-specific transfection, gain/loss-of-function studies The EMBO journal High 11331591
2000 CBFA1/RUNX2 autoregulates its own promoter through negative feedback: CBFA1 binds at least three recognition motifs in the rat CBFA1 P1 promoter and within the 5' UTR, and forced CBFA1 expression downregulates CBFA1 promoter activity; a single CBFA1 site is sufficient for transcriptional autosuppression. Deletion analysis, EMSA, promoter-reporter assays, forced expression Journal of cellular physiology High 10911365
2002 RUNX2 interacts with histone deacetylase 6 (HDAC6) via its carboxy-terminal domain (overlapping the nuclear matrix-targeting signal), recruits HDAC6 from the cytoplasm to chromatin, and represses the p21(CIP1/WAF1) promoter through this interaction in a trichostatin A-sensitive but trapoxin B-insensitive manner. Co-immunoprecipitation, co-localization by immunofluorescence, reporter gene assays, domain mapping, HDAC inhibitor treatment Molecular and cellular biology High 12391164
2006 BMP-2 signaling stimulates p300-mediated acetylation of RUNX2, which increases its transactivation activity and inhibits Smurf1-mediated ubiquitination and degradation; HDAC4 and HDAC5 deacetylate RUNX2, restoring susceptibility to Smurf-mediated degradation. HDAC inhibition potentiates BMP-2-stimulated osteoblast differentiation. In vivo acetylation assays, co-immunoprecipitation, ubiquitination assays, HDAC inhibitor treatment, osteoblast differentiation assays The Journal of biological chemistry High 16613856
2005 Smad6 physically interacts with RUNX2 (but not Smad7) and enhances Smurf1-induced RUNX2 degradation via the ubiquitin-proteasome pathway, acting as an adaptor for indirect Smurf1-mediated RUNX2 degradation independent of the PY motif. Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor studies, domain-deletion mutants The Journal of biological chemistry High 16299379
2008 CHIP/STUB1 E3 ubiquitin ligase interacts with RUNX2 in vitro and in vivo, promotes RUNX2 ubiquitination and proteasomal degradation, and negatively regulates osteoblast differentiation; CHIP depletion stabilizes RUNX2 and enhances osteoblast differentiation, while CHIP overexpression causes RUNX2 degradation and redirects progenitors toward adipogenesis. Co-immunoprecipitation, in vitro binding assay, ubiquitination assay, siRNA knockdown, overexpression in primary calvarial osteoblasts, differentiation assays The Journal of cell biology High 18541707
2005 Proper subnuclear targeting of RUNX2 via its nuclear matrix-targeting signal (NMTS) is required for its osteolytic and invasive functions; point mutations in the NMTS that impair targeting to nuclear matrix sites block invasive and osteolytic properties of MDA-MB-231 breast cancer cells and reduce VEGF and MMP13 expression. Site-directed mutagenesis of NMTS, immunofluorescence localization, in vivo osteolysis model, invasion assays, gene expression analysis Proceedings of the National Academy of Sciences of the United States of America High 15665096
2006 RUNX2 shuttles between the nucleus and cytoplasm in a microtubule-dependent and CRM1-dependent manner; taxol-induced microtubule stabilization causes CRM1-dependent nuclear export of RUNX2, and RUNX2 associates with stabilized microtubules via its amino terminus and co-immunoprecipitates with alpha-tubulin. Immunofluorescence microscopy, leptomycin B (CRM1 inhibitor) treatment, taxol treatment, co-immunoprecipitation with tubulin, biochemical microtubule association assay Journal of cellular physiology High 16110492
2003 Estrogen receptor (ER) physically interacts with RUNX2 as detected by co-immunoprecipitation; the interaction involves portions of RUNX2 outside the DNA binding domain and the DNA binding domain of ER, and estrogen enhances RUNX2 transcriptional activity in a dose- and ER-dependent manner without changing RUNX2 protein levels or DNA binding. Co-immunoprecipitation, two-hybrid gene expression analysis, domain deletion constructs, promoter-reporter assays The Journal of biological chemistry Medium 12951324
2002 1,25-(OH)2-vitamin D3 (VD3) suppresses the RUNX2/Cbfa1 promoter through a functional VDR/RXR heterodimer binding element in the proximal promoter region (−92 to −16); mutation of this VDRE abolished VD3 responsiveness, and VD3 suppression required functional vitamin D receptor. Promoter deletion analysis, EMSA with antibody competition, site-directed mutagenesis of VDRE, reporter gene assays in VDR-positive and -negative cells Experimental cell research High 11900492
2014 The C-terminus of RUNX2 (encoded by exon 8) drives its biological activity in chondrocytes; nuclear import and DNA binding functions of RUNX2 are insufficient for chondrogenesis, and Runx2 directly regulates a set of cell cycle genes (Gpr132, Sfn, c-Myb, Cyclin A1) to control chondrocyte proliferation. Conditional gene deletion (chondrocyte-specific Runx2 exon 8 flox), ChIP assay for cell cycle gene promoters, histology, molecular analysis Journal of bone and mineral research High 24862038
2014 Dlx5 and Mef2c directly bind to a 343-bp enhancer ~30 kb upstream of the RUNX2 distal promoter and are required for osteoblast-specific Runx2 expression; other factors (Tcf7, Ctnnb1, Sp7, Smad1, Sox6) associate with the enhancer through protein-protein interactions to synergistically activate it. The enhancer has characteristic active enhancer histone modifications (H3K4me1/2, H3K18ac, H3K27ac, H2A.Z). BAC-GFP reporter mice, serial deletion analysis, ChIP assay in primary osteoblasts, transcription factor binding site mutagenesis, chromatin immunoprecipitation for histone modifications Journal of bone and mineral research High 24692107
2003 Runx2 forms a physical complex with Sp7/Osterix via its Runt homology domain; co-expressed Runx2 and Sp7 synergistically activate osteocalcin and FGF3 promoters (up to 22- and 130-fold respectively), far exceeding effects of either alone. Co-immunoprecipitation of endogenous proteins, domain-deletion mapping, promoter-reporter assays in epithelial and mesenchymal cells Connective tissue research High 25158187
2020 Casein kinase 2 (CK2) phosphorylates RUNX2 and recruits the deubiquitinase HAUSP, which stabilizes RUNX2 by preventing ubiquitin-dependent proteasomal degradation. This CK2/HAUSP pathway is required for commitment of skeletal stem cells to osteoprogenitors, their maturation, and for heterotopic ossification in multiple models. In vitro kinase assay, co-immunoprecipitation, ubiquitination assays, genetic deletion models, pharmacological inhibition, heterotopic ossification models Nature communications High 32385263
2014 Akt increases the stability of RUNX2 protein by phosphorylating and promoting proteasomal degradation of Smurf2 (an E3 ubiquitin ligase for RUNX2), thereby alleviating Smurf2-mediated suppression of RUNX2 transcriptional activity; this mechanism does not involve direct modification of RUNX2 by Akt. Protein stability assays, ubiquitination assay, Smurf2 phosphorylation analysis, RUNX2 transcriptional activity reporter, co-immunoprecipitation The FEBS journal Medium 24961731
2008 p68 RNA helicase (Ddx5) interacts with RUNX2 in nuclear punctate foci and functions as a co-activator of RUNX2 transcription independently of its helicase activity; RUNX2 suppresses p68 expression in calvarial progenitor cells, establishing reciprocal crosstalk. Affinity purification/proteomics to identify RUNX2-interacting proteins, co-localization by immunofluorescence, transcription reporter assays, siRNA knockdown Journal of cellular biochemistry Medium 17960593
1999 AML3/CBFalpha1 (RUNX2) physically interacts with steroid receptors (AR and GR) via GST pull-down; AML3/CBFalpha1 shows preferential interaction with AR over GR and is functionally required for androgen-specific activation of the Slp enhancer, as dominant-negative AML1-ETO abrogates AR induction and AML3 overexpression rescues this repression. GST pull-down, EMSA with antibody supershift, dominant-negative construct, overexpression rescue assay The Journal of biological chemistry Medium 10521447
2003 Runx2 directly binds to and activates the galectin-3 promoter at two sites; forced Runx2 expression is sufficient to induce galectin-3 transcription in mesenchymal precursors, and galectin-3 expression is absent in Runx2-deficient mice. EMSA demonstrating direct Runx2 binding to galectin-3 promoter, forced expression assays in C3H10T1/2 cells, Runx2 knockout mouse analysis The Journal of biological chemistry High 12604608
2004 Cbfa1/RUNX2 binds to the proximal SOST promoter and contributes to differential SOST expression, as shown by gel shift and transient transfection analyses in two osteosarcoma cell lines. EMSA (gel shift) and transient transfection reporter assays The Journal of biological chemistry Medium 14739291
2004 FGF2 activates RUNX2 via the MEK/ERK signaling pathway and increases RUNX2 phosphorylation approximately 2-fold in articular chondrocytes; MEK/ERK inhibitors block both FGF2-induced RUNX2 activation and MMP-13 promoter upregulation. The authors note it is unlikely that RUNX2 is a direct ERK1/2 substrate. Pharmacological inhibition of MEK/ERK, RUNX2 phosphorylation assay, MMP-13 promoter-reporter assay, RUNX2 overexpression Osteoarthritis and cartilage Medium 15564063
2003 In human bone marrow stromal cells, RUNX2 osteoblastic differentiation activity increases through a posttranslational mechanism involving phosphorylation, without changes in mRNA or protein levels; immunoprecipitation and Western blot revealed increased RUNX2 phosphorylation during differentiation. Western blot, EMSA for DNA binding activity, immunoprecipitation/Western blot for phosphorylation, RT-PCR Journal of bone and mineral research Medium 12568398
2003 Runx2 directly binds to the survivin promoter (regions −1953 to −1812 and −1485 to −1119 containing consensus Runx-binding sites) in prostate cancer cells as shown by chromatin immunoprecipitation; BMP7 restores Runx2 binding to region II and Runx2 is required for survivin transcription. Chromatin immunoprecipitation (ChIP), reporter gene deletion assay, siRNA knockdown of RUNX2 Laboratory investigation Medium 19949374
2012 XBP1S associates physically with RUNX2 and enhances RUNX2-induced chondrocyte hypertrophy; XBP1S overexpression accelerates hypertrophy as measured by increased type X collagen and RUNX2, while XBP1S knockdown abolishes hypertrophic differentiation. Co-immunoprecipitation of XBP1S and RUNX2, overexpression, siRNA knockdown, chondrocyte differentiation markers The Journal of biological chemistry Medium 22865880
2010 RUNX2 functionally associates with TCF-4 (lacking beta-catenin binding domain) and is required for Wnt-dependent gene expression in osteoblasts; Wnt pathway induction enhances RUNX2 transcriptional potential in a beta-catenin-independent manner, and RUNX2 antisense depletion specifically suppresses Wnt-induced gene expression. Co-immunoprecipitation of RUNX2 with TCF-4, antisense depletion, reporter gene assays, prostaglandin E2 and Wnt pathway stimulation Molecular endocrinology Medium 20093419
2020 Runx2 is essential for the transdifferentiation of terminal hypertrophic chondrocytes into osteoblasts; conditional deletion of Runx2 in hypertrophic chondrocytes (Col10a1-Cre) increased their apoptosis and interrupted transdifferentiation, abolishing primary spongiosa and osteoblasts in the trabecular region at E16.5, but did not affect vascular invasion into cartilage. Conditional knockout (Runx2fl/fl Col10a1-Cre), lineage tracing, histology, immunohistochemistry, in situ hybridization PLoS genetics High 33253203
2022 Runx2 establishes chromatin accessibility in osteoblasts at cell-type-distinct regulatory regions; loss of Runx2 impairs chromatin opening at osteoblast-specific enhancers including an Sp7 distal enhancer that requires Runx2-dependent binding, as demonstrated by integrative ATAC-seq and ChIP-seq analysis in neonatal osteoblasts and chondrocytes. ATAC-seq, ChIP-seq, conditional Runx2 knockout, direct cellular reprogramming, functional enhancer reporter assays Cell reports High 36070691
2023 Glutathione (GSH) biosynthesis protects RUNX2 from ROS-induced degradation; reducing GSH led to acute RUNX2 protein degradation and impaired osteoblast differentiation, while reducing ROS with catalase enhanced RUNX2 stability. In utero antioxidant therapy stabilized RUNX2 and improved bone development in Runx2+/- mice. GSH biosynthesis inhibition, catalase overexpression, RUNX2 protein stability assays, CRISPR, antioxidant treatment in Runx2+/- mouse model JCI insight High 37432749
2024 4-Hydroxynonenal (4-HNE) directly carbonylates RUNX2 at lysine 176, increasing RUNX2 protein stability and promoting vascular smooth muscle cell calcification; mutation of K176 reduced carbonylation and eliminated 4-HNE-induced RUNX2 upregulation. Site-directed mutagenesis (K176 mutation), carbonylation assay, RUNX2 knockdown, ALDH2 knockout/transgenic mice, in vitro calcification model Circulation High 38348663
2003 RUNX2 is ectopically expressed in metastatic breast cancer cells and activates bone sialoprotein (BSP) expression through a Runx-binding element in the proximal −110 bp of the BSP promoter, establishing a mechanism for osteoblastic gene mimicry in breast cancer cells that preferentially metastasize to bone. Promoter deletion analysis, RUNX2 isoform-specific overexpression, reporter gene assays in breast cancer cell lines Cancer research Medium 12750290
2011 TIEG1/KLF10 directly binds to and activates the Runx2 promoter (via its zinc-finger domain), physically associates with Runx2 protein (co-immunoprecipitation and co-localization), and co-activates Runx2 transcriptional activity; loss of TIEG1 in knockout mice reduces Runx2 expression and impairs osteoblast mineralization. Transient transfection, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, co-localization, TIEG1 KO mouse analysis, adenoviral RUNX2 rescue PloS one Medium 21559363
2003 Runx2 directly binds to the DICER promoter and regulates its expression; Runx2 knockout mice display weaker DICER expression; DICER in turn cleaves precursors of miR-335-5p and miR-17-92 cluster, establishing a Runx2/DICER/miRNA cascade in osteogenic differentiation. Luciferase reporter assay for DICER promoter, Runx2 KO mouse analysis, siRNA targeting DICER, miRNA profiling, in vivo bone defect model Journal of cellular physiology Medium 27064596
2025 RUNX2 is a key regulator of fibrotic gene expression in LEPR+ fibroblasts; conditional deletion of Runx2 using LeprcreERT2 or Scube2creERT2 reduces generation of pathological CTHRC1+POSTN+ fibroblasts, extracellular matrix deposition, and pulmonary fibrosis in mouse models, as identified by scRNA-seq and scATAC-seq analysis. Conditional knockout (LeprcreERT2, Scube2creERT2), scRNA-seq, scATAC-seq, mouse models of pulmonary fibrosis, genetic ablation of POSTN+ cells Nature High 39910313
2016 RUNX2 and Osterix (OSX) physically bind to a specific region close to the SOST transcription start site and co-ordinately activate SOST expression; co-transfection of OSX and RUNX2 activates the SOST promoter in vitro. Chromatin immunoprecipitation (ChIP), promoter-reporter assays, co-transfection in osteoblastic cells Calcified tissue international Medium 27154028
2003 Cbfb (core binding factor beta) forms a heterodimer with RUNX2 and is required for efficient DNA binding of RUNX2; Cbfb stabilizes RUNX2 protein by inhibiting its ubiquitination-mediated degradation. Heterodimer interaction studies, DNA binding assays, ubiquitination assays, genetic models Journal of bone and mineral metabolism Medium 12811622
2010 Runx1 and Runx2 cooperatively regulate sternal morphogenesis and chondrocyte commitment through direct regulation of Sox5 and Sox6 promoter activity, leading to induction of alpha1(II) collagen expression; mesenchymal-cell-specific double knockout of Runx1/Runx2 completely abolishes sternum formation. Conditional knockout mice (Prx1-Cre double knockout), in situ hybridization, promoter activity assays, histology Development High 20181744
2003 RUNX2 directly binds to the RUNX2 promoter in osseous cells (confirmed by EMSA in competition assays), and there are at least three CBFA1 recognition motifs plus three tandemly repeated sites in the 5' UTR, establishing transcriptional autosuppression as a regulatory mechanism. EMSA with competition and antibody supershift, deletion analysis, forced expression reporter assays Journal of cellular physiology High 10911365

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 3462 9182762
2019 Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2. International journal of molecular sciences 600 30987410
2000 Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocrine reviews 507 10950158
2014 Role and regulation of RUNX2 in osteogenesis. European cells & materials 441 25340806
2001 TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. The EMBO journal 438 11331591
1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. Journal of cellular biochemistry 394 10412038
2001 Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. The Journal of biological chemistry 379 11723115
2018 Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochemistry and cell biology 372 29356961
1994 AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 366 7835892
1997 Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. Journal of cellular biochemistry 348 9215522
2000 Cbfa1: a molecular switch in osteoblast biology. Developmental dynamics : an official publication of the American Association of Anatomists 324 11084646
2015 Runx2: Structure, function, and phosphorylation in osteoblast differentiation. International journal of biological macromolecules 296 25881954
2006 Bone morphogenetic protein-2 stimulates Runx2 acetylation. The Journal of biological chemistry 291 16613856
2002 Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Molecular and cellular biology 275 12391164
2011 Signaling networks in RUNX2-dependent bone development. Journal of cellular biochemistry 259 21328448
2005 Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth defects research. Part C, Embryo today : reviews 255 16187316
2002 Runx2, a multifunctional transcription factor in skeletal development. Journal of cellular biochemistry 255 12210716
2004 Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. Osteoarthritis and cartilage 244 15564063
2002 Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Human mutation 227 11857736
2009 Runx2, osx, and dspp in tooth development. Journal of dental research 223 19783797
2000 Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. Journal of cellular physiology 217 10911365
2003 Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 192 12568398
2008 Regulation of bone development and maintenance by Runx2. Frontiers in bioscience : a journal and virtual library 189 17981598
1999 CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Human molecular genetics 183 10545612
2020 Molecular Mechanism of Runx2-Dependent Bone Development. Molecules and cells 181 31896233
2003 Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connective tissue research 181 12952183
2022 Whole Aspect of Runx2 Functions in Skeletal Development. International journal of molecular sciences 174 35628587
2001 Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology 172 11517182
2003 Requisite roles of Runx2 and Cbfb in skeletal development. Journal of bone and mineral metabolism 171 12811622
2003 Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer research 165 12750290
2017 Roles of Runx2 in Skeletal Development. Advances in experimental medicine and biology 161 28299652
2005 Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proceedings of the National Academy of Sciences of the United States of America 149 15665096
2001 Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. Journal of cellular biochemistry 146 11135373
2005 Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 137 16079892
2009 Post-translational Regulation of Runx2 in Bone and Cartilage. Journal of dental research 134 19734454
2002 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Experimental cell research 132 11900492
2003 Runx2/Cbfa1: a multifunctional regulator of bone formation. Current pharmaceutical design 130 14529540
2005 Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. The Journal of biological chemistry 128 16299379
2014 Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 127 24862038
2006 Runx2 and dental development. European journal of oral sciences 117 17026500
2007 Runx2: of bone and stretch. The international journal of biochemistry & cell biology 107 17656144
2006 Transcriptional co-repressors of Runx2. Journal of cellular biochemistry 106 16440320
2014 Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 102 24692107
2020 Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts. PLoS genetics 100 33253203
2008 CHIP promotes Runx2 degradation and negatively regulates osteoblast differentiation. The Journal of cell biology 94 18541707
2003 Runx2 integrates estrogen activity in osteoblasts. The Journal of biological chemistry 94 12951324
2005 Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development. Journal of cellular physiology 91 15389629
2014 Akt enhances Runx2 protein stability by regulating Smurf2 function during osteoblast differentiation. The FEBS journal 90 24961731
2019 Regulation of Runx2 by MicroRNAs in osteoblast differentiation. Life sciences 87 31340165
2020 RUNX2-modifying enzymes: therapeutic targets for bone diseases. Experimental & molecular medicine 82 32788656
2019 Runx2 plays a central role in Osteoarthritis development. Journal of orthopaedic translation 81 32913706
2002 Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells. Molecular and cellular endocrinology 80 12088880
2010 Runx1 and Runx2 cooperate during sternal morphogenesis. Development (Cambridge, England) 77 20181744
2003 Expression of galectin-3 in skeletal tissues is controlled by Runx2. The Journal of biological chemistry 75 12604608
2016 Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone. Calcified tissue international 73 27154028
2020 A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nature communications 72 32385263
2018 KLF2 regulates osteoblast differentiation by targeting of Runx2. Laboratory investigation; a journal of technical methods and pathology 71 30429507
2004 Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). The Journal of biological chemistry 67 14739291
2008 p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation. Journal of cellular biochemistry 66 17960593
2013 RUNX2 in mammary gland development and breast cancer. Journal of cellular physiology 65 23169547
2009 Runx2 regulates survivin expression in prostate cancer cells. Laboratory investigation; a journal of technical methods and pathology 64 19949374
2010 Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARγ and adiponectin. Journal of cellular physiology 63 20589837
2022 Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages. Cell reports 59 36070691
2006 Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2. Journal of cellular physiology 59 16110492
2003 Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connective tissue research 59 12952188
2002 p107 and p130 Coordinately regulate proliferation, Cbfa1 expression, and hypertrophic differentiation during endochondral bone development. Developmental biology 59 12086466
2008 Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 58 19075196
2023 Glutathione limits RUNX2 oxidation and degradation to regulate bone formation. JCI insight 53 37432749
2020 Post-Translational Regulations of Transcriptional Activity of RUNX2. Molecules and cells 52 31878768
2025 RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition. Nature 51 39910313
2018 CircRUNX2 through has-miR-203 regulates RUNX2 to prevent osteoporosis. Journal of cellular and molecular medicine 50 30324718
2005 Control of RUNX2 isoform expression: the role of promoters and enhancers. Journal of cellular biochemistry 49 15838892
2008 Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Molecular biology reports 48 18931939
2015 Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood 47 25862559
2024 Regulation of Skeletal Development and Maintenance by Runx2 and Sp7. International journal of molecular sciences 45 39337587
2015 Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 45 25079226
2015 Role of RUNX2 in Breast Carcinogenesis. International journal of molecular sciences 45 26404249
2022 RUNX2 Regulates Osteoblast Differentiation via the BMP4 Signaling Pathway. Journal of dental research 44 35619284
2018 Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p. Biochimie 44 30562548
2010 Novel links among Wnt and TGF-beta signaling and Runx2. Molecular endocrinology (Baltimore, Md.) 44 20093419
2000 PEBP2alphaA/CBFA1 mutations in Japanese cleidocranial dysplasia patients. Gene 44 10689183
1999 AML3/CBFalpha1 is required for androgen-specific activation of the enhancer of the mouse sex-limited protein (Slp) gene. The Journal of biological chemistry 44 10521447
2016 Runx2/DICER/miRNA Pathway in Regulating Osteogenesis. Journal of cellular physiology 43 27064596
2003 IRES-dependent translational control of Cbfa1/Runx2 expression. Journal of cellular biochemistry 40 12532326
2011 TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PloS one 37 21559363
2015 RUNX2 and Osteosarcoma. Anti-cancer agents in medicinal chemistry 36 25738872
2014 RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer letters 35 24657655
2023 RUNX2 and Cancer. International journal of molecular sciences 33 37108164
2015 GnRH regulates trophoblast invasion via RUNX2-mediated MMP2/9 expression. Molecular human reproduction 33 26660506
2013 RUNX2 mutations in cleidocranial dysplasia. Genetics and molecular research : GMR 33 24222232
2024 Carbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification. Circulation 31 38348663
2007 Cbfa1/Runx2-deficiency delays bone wound healing and locally delivered Cbfa1/Runx2 promotes bone repair in animal models. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 31 17537128
2001 Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia. Journal of inherited metabolic disease 31 11768584
2021 Smoc1 and Smoc2 regulate bone formation as downstream molecules of Runx2. Communications biology 29 34667264
2021 RUNX2 promotes malignant progression in gastric cancer by regulating COL1A1. Cancer biomarkers : section A of Disease markers 28 33896817
2018 Deletion of Runx2 in condylar chondrocytes disrupts TMJ tissue homeostasis. Journal of cellular physiology 28 30387127
2014 Sp7 and Runx2 molecular complex synergistically regulate expression of target genes. Connective tissue research 27 25158187
2003 Tooth eruption and cementum formation in the Runx2/Cbfa1 heterozygous mouse. Archives of oral biology 27 12888002
2015 Runx2 contributes to the regenerative potential of the mammary epithelium. Scientific reports 26 26489514
2012 XBP1S associates with RUNX2 and regulates chondrocyte hypertrophy. The Journal of biological chemistry 26 22865880

Missed literature

Know a paper Affinage missed for RUNX2? Flag it for the maintainers and the community.

No submissions yet.